Patienternes antitrombinaktivitet skal løbende overvåges i hele behandlingsperioden, hvor den skal holdes på mindst 80% af normalværdien.
The patients should be continually monitored to adjust the infusion rate so that their antithrombin activity is at least 80% of the normal level for the duration of the treatment.